AndyForce "CureBio to Participate in 'BioUSA'... Full-Scale Discussions on Technology Transfer"

[Asia Economy Reporter Hyunseok Yoo] CureBio announced on the 12th that it participated in the '2020 BIO International Convention' (BIO USA), held online. The company is conducting joint clinical trials and technology transfer negotiations with global pharmaceutical companies regarding its clinical-stage protein synthesis element (Aminoacyl-tRNA synthetase, ARS) peptide-based pipeline.

A CureBio official stated, “Global pharmaceutical companies showed great interest in the ARS peptide-based pipeline, and in particular, we have reached a concrete agreement on joint clinical trials and technology transfer of the Neopep GT pipeline for kidney cancer treatment with a well-known Japanese global pharmaceutical company.”

Neopep GT is a new drug developed by CureBio targeting intractable kidney cancer, ovarian cancer, and liver cancer using the GRS (Glycyl tRNA Synthetase) protein peptide. The GRS protein selectively binds to the CDH6 protein, which is overexpressed on the surface of cancer cells, causing the cancer cells to die. Unlike existing immuno-oncology drugs, it removes cancer cells in the same way as the human immune system, and because it only attaches to cancer cells with high CDH6 expression, it has significantly fewer side effects and higher safety compared to chemotherapy drugs that kill normal cells as well.

Meanwhile, BIO USA is the world's largest global conference in the pharmaceutical and bio industry, with about 10,000 experts and stakeholders from over 70 countries in the fields of bio, pharmaceuticals, life sciences, and healthcare participating annually. This event is being held digitally and non-face-to-face due to the impact of COVID-19. Currently, many global pharmaceutical companies such as PharmAbcine, Johnson & Johnson, Pfizer, AbbVie, and Merck are participating.

This content was produced with the assistance of AI translation services.